Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer

Triple negative breast cancer (TNBC) is the most aggressive accounting for around 15% of identified cases. TNBC lacks human epidermal growth factor receptor 2 (HER2) amplification, hormone independent estrogen (ER) and progesterone receptors (PR) negative, not reactive to current targeted therapies. Existing treatment relies on chemotherapeutic treatment, but in spite an initial response chemotherapy, inception resistance relapse unfortunately common. Dasatinib approved second-generation inhibitor multiple tyrosine kinases, literature data strongly support its use management TNBC. However, dasatinib binds plasma proteins undergoes extensive metabolism through oxidation conjugation. To protect from fast pharmacokinetic degradation prolong activity, it was encapsulated poly(styrene-co-maleic acid) (SMA) micelles. The obtained SMA–dasatinib nanoparticles (NPs) were evaluated their physicochemical properties, vitro antiproliferative activity different cell lines, vivo anticancer a syngeneic model cancer. Obtained results showed that more potent against 4T1 tumor compared free drug. This enhanced effect ascribed encapsulation drug protecting rapid metabolism. Our finding highlights often-overlooked value nanoformulations cargo degradation. Overall, may provide alternative therapeutic strategy management.